Mycophenolic acid 12-h trough level monitoring in renal transplantation: Association with acute rejection and toxicity

被引:119
作者
Borrows, R [1 ]
Chusney, G
Loucaidou, M
James, A
Lee, J
Tromp, JV
Owen, J
Cairns, T
Griffith, M
Hakim, N
McLean, A
Palmer, A
Papalois, V
Taube, D
机构
[1] St Marys Hosp, Renal & Transplant Unit, London W2 1NY, England
[2] St Marys Hosp, Brent Lab, London W2 1NY, England
关键词
drug monitoring; mycophenolic acid; renal; transplant;
D O I
10.1111/j.1600-6143.2005.01151.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Studies of renal transplantation utilizing trough plasma level monitoring of mycophenolic acid (MPA) have shown inconsistent associations with toxicity and rejection. In this study, 5600 12-h trough MPA samples from 121 renal transplant recipients immunosuppressed with mycophenolate mofetil (MMIF) and tacrolimus in a steroid sparing protocol (steroids for 7 days only) were sequentially analyzed. Higher MPA levels were associated with lower hemoglobin concentrations and anemia (hemoglobin < 10 g/dL). Similarly, higher MPA levels were associated with lower total white cell counts and an increased incidence of leucopenia (total white cell count < 4.0 x 10(9)/L). Hypoalbuminemia and renal impairment were also associated with hemotoxicity. MMF-associated diarrhea and viral infection were associated with higher MPA levels. Conversely, biopsyproven acute rejection within the first month post-transplantation was associated with lower MPA levels. Anti-CD25 antibody induction was also associated with reduced rejection rates. No association was seen between MPA levels and platelet count, thrombocytopenia or bacterial infection. An MPA level of 1.60 mg/L early post-transplantation best discriminated patients with and without rejection, and an MPA level of 2.75 mg/L best discriminated patients with and without toxicity later post-transplantation.
引用
收藏
页码:121 / 128
页数:8
相关论文
共 38 条
[1]  
ALTMAN DG, 1991, PRACTICAL STAT MED R, P466
[2]   Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant [J].
Atcheson, BA ;
Taylor, PJ ;
Mudge, DW ;
Johnson, DW ;
Hawley, CM ;
Campbell, SB ;
Isbel, NM ;
Pillans, PI ;
Tett, SE .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (03) :271-280
[3]   Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia [J].
Atcheson, BA ;
Taylor, PJ ;
Kirkpatrick, CMJ ;
Duffull, SB ;
Mudge, DW ;
Pillans, PI ;
Johnson, DW ;
Tett, SE .
THERAPEUTIC DRUG MONITORING, 2004, 26 (03) :284-286
[4]   Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation [J].
Borrows, R ;
Loucaidou, M ;
Van Tromp, J ;
Cairns, T ;
Griffith, M ;
Hakim, N ;
McLean, A ;
Palmer, A ;
Papalois, V ;
Taube, D .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (11) :1845-1851
[5]   Clinical pharmacokinetics of mycophenolate mofetil [J].
Bullingham, RES ;
Nicholls, AJ ;
Kanmm, BR .
CLINICAL PHARMACOKINETICS, 1998, 34 (06) :429-455
[6]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[7]   The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression [J].
Flechner, SM ;
Feng, L ;
Mastroianni, B ;
Savas, K ;
Arnovitz, J ;
Moneim, H ;
Modlin, CS ;
Goldfarb, D ;
Cook, DJ ;
Novick, AC .
TRANSPLANTATION, 2005, 79 (08) :926-934
[8]  
GRINYO J, 1995, LANCET, V345, P1321
[9]   Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2 [J].
Hesselink, DA ;
van Hest, RM ;
Mathot, RAA ;
Bonthuis, F ;
Weimar, W ;
de Bruin, RWF ;
van Gelder, T .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (05) :987-994
[10]  
Huber PJ, 1967, 5 BERK S MATH STAT P, P221